Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Third-Quarter Sales Better -Than- Expected for LinkedIn, Thanks to New Businesse
“Overweight” Rating for Facebook from JPMorgan Chase & Co
Fall in Oil prices Leave the Small-cap Shale Companies in Trouble
Beginning of 2015, Starbucks will Start its Delivery Service in Selected Markets
Herb Strather, Detroit blight Buyer Makes a Wednesday Deadline
Baidu with its Growing Mobile Presence, Hit 27 Percent Profit Increase
Third Quarter Profits for Samsung Electronics Drop Sharply
Federal Reserve Ends Bond Buying Programme, Keeps Interest Rates Low
Reduced Growth in Major Overseas Economies Affect U.S. Durable Goods Order
Lowe’s to Introduce Robots in Store for Customer Service
Facebook Shares Fall as the Company Portrays Increased in Expenses in 2015
USPS Audit Questions the Consistency of Surveillance Conducted on Mail